The amount of money that the biopharma sector invests in research and development (R&D) continues to rise. Innovation certainly does not come cheap; it requires that companies developing breakthrough medicines have deep pockets as they need to invest up to $2.5 billion over a 10- to 15-year period in order to bring a new therapy to the marketplace, according to the most recent analysis by the Tufts Center for the Study of Drug Development of the average cost to develop and gain marketing approval for a new drug.